Treatment of systemic lupus erythematosus: don’t forget hydroxychloroquine ============================================================================ * Martin Michaud * Florian Catros * Sophie Ancellin * Francis Gaches * treatment * systemic lupus erythematosus * lupus nephritos * guidelines * EULAR We read with interest the last 2019 update of the European League Against Rheumatism recommendations for the management of systemic lupus erythematosus (SLE).1 We agree with the comment by Gabriel Figueroa-Parra *et al* concerning the lack of mention of chloroquine as major treatment in SLE.2 Concerning survival, the LUMINA study group also showed that use of hydroxychloroquine (HCQ) was associated with a greater survival rate in 608 patients with SLE.3 Ruiz-Irastorza *et al* confirmed these results in 232 patients with SLE.4 The 15-year survival rate was 0.95 for patients using HCQ versus 0.68 for patients without antimalarial therapy. Finally, use of HCQ was also independently associated with a greater survival in a population of patients with SLE with nephritis.5 The LUpus in MInorities, NAture versus nurture (LUMINA) study group also showed that patients without HCQ had higher damage scores and were more likely to have renal disease or central nervous system disease and use of HCQ was associated with a reduced risk of developing new damage in multivariate analysis.3 The Canadian Hydroxychloroquine Study Group realised a double-blinded, placebo-controlled study that included patients with SLE to compare HCQ with placebo.6 The risk of SLE flares (including major flares) increased by 2.5 at the end of the 6-months follow-up period in the placebo group compared with the HCQ group. During the additional 3 years follow-up study, use of HCQ reduced major flares by 57%.7 Meinao *et al* published another double-blind placebo-controlled trial with chloroquine diphosphate steroid requirements and SLE Disease Activity Index score were higher in the placebo group and the flare risk was 4.6 times greater in the placebo group.8 Moreover, patients with lower blood HCQ concentrations have greater SLE disease activity and have a greater risk of disease flare.9 10 During pregnancy, HCQ use is essential. It reduces risks of pre-eclampsia, cutaneous neonatal lupus erythematosus, fetal growth restriction and prematurity.11–13 In conclusion, HCQ is still in 2019, the cornerstone of the treatment of SLE. ## Footnotes * Contributors All authors contributed to write the manuscript. * Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. * Competing interests None declared. * Patient consent for publication Not required. * Provenance and peer review Not commissioned; internally peer reviewed. ## References 1. Fanouriakis A , Kostopoulou M , Alunno A , et al . 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019;78:736–45.[doi:10.1136/annrheumdis-2019-215089](http://dx.doi.org/10.1136/annrheumdis-2019-215089) pmid:http://www.ncbi.nlm.nih.gov/pubmed/30926722 [Abstract/FREE Full Text](http://ard.bmj.com/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTE6ImFubnJoZXVtZGlzIjtzOjU6InJlc2lkIjtzOjg6Ijc4LzYvNzM2IjtzOjQ6ImF0b20iO3M6Mjg6Ii9hbm5yaGV1bWRpcy83OS8xMC9lMTMzLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 2. Gabriel Figueroa-Parra G , Gamboa-Alonso CM , De-Leon-Ibarra AL , et al . update of the EULAR recommendations for the management of SLE: don’t forget chloroquine. Ann Rheum Dis 2020;79:e133. 3. Alarcón GS , McGwin G , Bertoli AM , et al . Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007;66:1168–72.[doi:10.1136/ard.2006.068676](http://dx.doi.org/10.1136/ard.2006.068676) [Abstract/FREE Full Text](http://ard.bmj.com/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTE6ImFubnJoZXVtZGlzIjtzOjU6InJlc2lkIjtzOjk6IjY2LzkvMTE2OCI7czo0OiJhdG9tIjtzOjI4OiIvYW5ucmhldW1kaXMvNzkvMTAvZTEzMy5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 4. Ruiz-Irastorza G , Egurbide M-V , Pijoan J-I , et al . Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006;15:577–83.[doi:10.1177/0961203306071872](http://dx.doi.org/10.1177/0961203306071872) [CrossRef](http://ard.bmj.com/lookup/external-ref?access_num=10.1177/0961203306071872&link_type=DOI) [PubMed](http://ard.bmj.com/lookup/external-ref?access_num=17080912&link_type=MED&atom=%2Fannrheumdis%2F79%2F10%2Fe133.atom) [Web of Science](http://ard.bmj.com/lookup/external-ref?access_num=000241996300004&link_type=ISI) 5. Zheng ZH , Zhang LJ , Liu WX , et al . Predictors of survival in Chinese patients with lupus nephritis. Lupus 2012;21:1049–56.[doi:10.1177/0961203312445230](http://dx.doi.org/10.1177/0961203312445230) [CrossRef](http://ard.bmj.com/lookup/external-ref?access_num=10.1177/0961203312445230&link_type=DOI) [PubMed](http://ard.bmj.com/lookup/external-ref?access_num=22513365&link_type=MED&atom=%2Fannrheumdis%2F79%2F10%2Fe133.atom) [Web of Science](http://ard.bmj.com/lookup/external-ref?access_num=000307450800003&link_type=ISI) 6. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991;324:150–4.[doi:10.1056/NEJM199101173240303](http://dx.doi.org/10.1056/NEJM199101173240303) [CrossRef](http://ard.bmj.com/lookup/external-ref?access_num=10.1056/NEJM199101173240303&link_type=DOI) [PubMed](http://ard.bmj.com/lookup/external-ref?access_num=1984192&link_type=MED&atom=%2Fannrheumdis%2F79%2F10%2Fe133.atom) [Web of Science](http://ard.bmj.com/lookup/external-ref?access_num=A1991ER47100003&link_type=ISI) 7. Tsakonas E , Joseph L , Esdaile JM , et al . A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythemato- Sus. Lupus 1998;7:80–5. [CrossRef](http://ard.bmj.com/lookup/external-ref?access_num=10.1191/096120398678919778&link_type=DOI) [PubMed](http://ard.bmj.com/lookup/external-ref?access_num=9541091&link_type=MED&atom=%2Fannrheumdis%2F79%2F10%2Fe133.atom) [Web of Science](http://ard.bmj.com/lookup/external-ref?access_num=000072536400005&link_type=ISI) 8. Meinão IM , Sato EI , Andrade L , et al . Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus 1996;5:237–41.[doi:10.1177/096120339600500313](http://dx.doi.org/10.1177/096120339600500313) [PubMed](http://ard.bmj.com/lookup/external-ref?access_num=8803897&link_type=MED&atom=%2Fannrheumdis%2F79%2F10%2Fe133.atom) [Web of Science](http://ard.bmj.com/lookup/external-ref?access_num=A1996UW99500013&link_type=ISI) 9. Costedoat-Chalumeau N , Amoura Z , Hulot J-S , et al . Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:3284–90.[doi:10.1002/art.22156](http://dx.doi.org/10.1002/art.22156) [CrossRef](http://ard.bmj.com/lookup/external-ref?access_num=10.1002/art.22156&link_type=DOI) [PubMed](http://ard.bmj.com/lookup/external-ref?access_num=17009263&link_type=MED&atom=%2Fannrheumdis%2F79%2F10%2Fe133.atom) [Web of Science](http://ard.bmj.com/lookup/external-ref?access_num=000241260800028&link_type=ISI) 10. Costedoat-Chalumeau N , Galicier L , Aumaître O , et al . Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (plus study). Ann Rheum Dis 2013;72:1786–92.[doi:10.1136/annrheumdis-2012-202322](http://dx.doi.org/10.1136/annrheumdis-2012-202322) [Abstract/FREE Full Text](http://ard.bmj.com/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTE6ImFubnJoZXVtZGlzIjtzOjU6InJlc2lkIjtzOjEwOiI3Mi8xMS8xNzg2IjtzOjQ6ImF0b20iO3M6Mjg6Ii9hbm5yaGV1bWRpcy83OS8xMC9lMTMzLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 11. Seo MR , Chae J , Kim YM , et al . Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia. Lupus 2019;28:722–30.[doi:10.1177/0961203319843343](http://dx.doi.org/10.1177/0961203319843343) 12. Barsalou J , Costedoat-Chalumeau N , Berhanu A , et al . Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus. Ann Rheum Dis 2018;77:1742–9.[doi:10.1136/annrheumdis-2018-213718](http://dx.doi.org/10.1136/annrheumdis-2018-213718) [Abstract/FREE Full Text](http://ard.bmj.com/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTE6ImFubnJoZXVtZGlzIjtzOjU6InJlc2lkIjtzOjEwOiI3Ny8xMi8xNzQyIjtzOjQ6ImF0b20iO3M6Mjg6Ii9hbm5yaGV1bWRpcy83OS8xMC9lMTMzLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 13. Guillotin V , Bouhet A , Barnetche T , et al . Hydroxychloroquine for the prevention of fetal growth restriction and prematurity in lupus pregnancy: a systematic review and meta-analysis. Joint Bone Spine 2018;85:663–8.[doi:10.1016/j.jbspin.2018.03.006](http://dx.doi.org/10.1016/j.jbspin.2018.03.006)